Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity NEW YORK, April 13, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company,...
Hence then, the article about hoth therapeutics hoth reports positive ht va crada data gdnf reprograms liver fat metabolism shuts down fat creation gene and activates fat burning pathways outperforming semaglutide was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide )
Also on site :